Welcome to our dedicated page for POMDOCTOR SEC filings (Ticker: POM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on POMDOCTOR's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into POMDOCTOR's regulatory disclosures and financial reporting.
POMDOCTOR Ltd (POM), a digital healthcare company focused on AI-enabled and predictive healthcare, reported multi‑year growth and outlined a global expansion plan while announcing participation in H.C. Wainwright’s 28th Annual Global Investment Conference. A virtual presentation will be available beginning September 11, 2026, and management will hold one‑on‑one investor meetings during the September 14‑16, 2026 event.
Net revenues rose from RMB 304.9 million in FY2023 to RMB 399.9 million in FY2025, and gross profit increased to RMB 130.9 million with a 13.9% gross margin, while the company remained loss‑making with FY2025 net loss of RMB 52.3 million212,800, more than 699,338 paying patients and over 3.13 million prescriptions processed. POMDOCTOR presents a roadmap centered on building a predictive healthcare data and services infrastructure, a US$30 million capital‑raising plan primarily for U.S. market entry and AI/data infrastructure, and a phased global rollout beginning with a U.S. launch at CES 2027.
POMDOCTOR Ltd (POM) has called an extraordinary general meeting for September 30, 2026 to seek shareholder approval for terminating its American Depositary Receipt (ADR) program and moving to a direct listing of its Class A ordinary shares on Nasdaq. The ADR termination and direct listing are intended to occur on the same date and are presented as an advisory, non-binding resolution.
Shareholders are also being asked to approve a 10‑to‑1 Share Consolidation of all share classes, changing par value from US$0.0001 to US$0.001 per share and reducing authorized share capital from 500,000,000 to 50,000,000 shares while keeping total authorized capital at US$50,000. No fractional shares will be issued; any fractions will be rounded up to the nearest whole share at the participant level. As of the September 2, 2026 record date, 27,802,964 ordinary shares were outstanding, consisting of 25,760,922 Class A shares with one vote each and 2,042,042 Class B shares with twenty votes each. A third proposal would allow adjournment of the meeting to solicit additional proxies if needed.
POMDOCTOR Ltd (POM), a China-based digital healthcare company focused on AI-enabled solutions, announced it has formally begun preparations to enter the U.S. market as part of its global growth strategy. The company is recruiting U.S.-based leadership and operational staff, has completed an initial assessment of the U.S. healthcare market, and is building a local compliance and regulatory framework.
POMDOCTOR is also localizing its products and holding exploratory discussions with potential U.S. partners. The expansion will follow a multi-phase approach starting with pilot validation, including potential use cases in remote patient monitoring and chronic disease management, followed by deeper engagement with payers and providers and, if successful, progressive commercial scaling across selected U.S. regions.
POMDOCTOR LIMITED, a digital healthcare company focused on AI-enabled and predictive healthcare solutions, describes its healthcare intelligence flywheel, a closed-loop model integrating wearable devices, healthcare data, AI analytics, physician services, and insurance payment networks. The model is intended to let each service cycle generate additional data, strengthen AI capabilities, and improve service personalization and user engagement.
The company explains that repeated healthcare service cycles are designed to deepen and diversify real-world healthcare data, enhance individualized risk assessment and recommendations, and improve user retention. Management states that the company’s competitive position relies on orchestrating data collection, AI analysis, professional medical services, pharmaceutical fulfillment, and payment networks into a unified ecosystem that becomes harder to replicate over time.
POMDOCTOR LIMITED, a digital healthcare company listed on NASDAQ, outlined a four-tier diversified revenue structure designed to build on its established internet hospital, physician network and pharmaceutical supply chain while scaling technology-enabled services. The four tiers are B2C basic healthcare services, AI-enabled chronic disease membership subscriptions, B2B enterprise and hospital services, and pharmaceutical real-world study (RWS) and real-world data (RWD) services.
The company reported audited net revenues of RMB399.9 million (approximately US$59.04 million) for fiscal 2025, compared with RMB304.9 million in 2023 and RMB342.6 million in 2024, and believes this growth provides a foundation for additional AI-driven, recurring and institutional revenue streams. Management emphasized that traditional healthcare operations remain central, while AI, wearable technologies, remote patient monitoring and data capabilities are being integrated to build a predictive healthcare data and services infrastructure.
POMDOCTOR LIMITED, a digital healthcare company listed on NASDAQ, describes its strategy to build a healthcare data ecosystem to support AI-powered chronic disease management and predictive healthcare services. The company aggregates real-world data from wearable devices, remote patient monitoring, physician interactions, patient health management and healthcare payment-related activities.
Management emphasizes that high-quality real-world data is a core asset for AI platforms and expects continuous data flows to improve AI models and risk analysis. Industry research cited in the report projects strong global growth in real-world data markets, driven by electronic health records, telehealth, wearable devices and demand for personalized medicine.
POMDOCTOR LIMITED, a digital healthcare company listed on Nasdaq under the symbol POM, reports that it has regained compliance with Nasdaq’s minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5450(a)(1). Nasdaq notified the company on July 10, 2026 that the matter is closed after its American Depositary Shares (ADSs) maintained a closing bid price at or above $1.00 for 10 consecutive business days from June 25 to July 9, 2026.
The company had previously received a Nasdaq notice on January 29, 2026 after its ADS closing bid price stayed below $1.00 for 30 consecutive business days. With compliance restored, POMDOCTOR’s ADSs will continue to be listed on Nasdaq, and the company continues to focus on AI-enabled and predictive healthcare solutions.
POMDOCTOR LIMITED outlined its strategy to build an AI-enabled chronic disease management ecosystem, integrating artificial intelligence, remote patient monitoring, wearable technologies and real-world healthcare data. The company aims to shift care from reactive treatment toward predictive, continuous and personalized healthcare services.
The update highlights third-party research projecting rapid growth for AI chronic disease prevention and digital chronic disease management markets over the next decade, underscoring rising demand for predictive analytics and remote monitoring solutions. Management emphasized continued investment in technology capabilities and ecosystem partnerships to support its long-term vision for predictive healthcare infrastructure.
POMDOCTOR LIMITED, a China-based digital healthcare company, has announced a strategic upgrade, repositioning itself as a foundational infrastructure provider for predictive healthcare data and services rather than a traditional online consultation platform.
The company plans to integrate wearable devices, artificial intelligence, physician resources, real-world healthcare data and healthcare payment networks into a single intelligent ecosystem. This platform is intended to support continuous monitoring, early risk identification, diagnosis, treatment, rehabilitation and long-term chronic disease management with diversified revenue streams beyond pharmaceutical sales.
POMDOCTOR describes a healthcare intelligence “flywheel” in which wearable data feed an analysis and prediction engine, inform physician intervention, and connect with insurers to support value-based care. Management highlights chronic disease trends, advances in AI and remote monitoring, and shifting reimbursement models as key drivers, and notes ambitions to expand internationally, with the United States as an important next step.
POMDOCTOR LIMITED is implementing an ADS ratio change that will take effect on June 22, 2026, U.S. Eastern Time. Each American depositary share will change from representing one-sixth of a Class A ordinary share to representing three Class A ordinary shares.
For ADS holders, this functions as a one-for-eighteen reverse ADS split: every eighteen existing ADSs will be automatically exchanged for one new ADS, with no action required by holders. No changes are being made to the underlying Class A ordinary shares.
POMDOCTOR’s ADSs are expected to begin trading on Nasdaq on a post-reverse ADS split basis under the same ticker “POM” on the effective date. The company states that the ADS trading price is expected to increase proportionally, but it gives no assurance that the post-change price will equal or exceed eighteen times the prior price.